本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Kiniksa Pharmaceuticals Ltd.

34.20
+0.71002.12%
成交量:37.66万
成交额:1,282.90万
市值:25.34亿
市盈率:517.90
高:34.51
开:33.93
低:33.54
收:33.49
52周最高:34.55
52周最低:17.82
股本:7,410.77万
流通股本:3,355.22万
量比:1.25
换手率:1.12%
股息:- -
股息率:- -
每股收益(TTM):0.0660
每股收益(LYR):-0.6047
净资产收益率:1.03%
总资产收益率:0.46%
市净率:5.12
市盈率(LYR):-56.55

数据加载中...

2025/03/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/03/10

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/02/26

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/02/26

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/25

重要事件披露

Form 8-K - Current report
2025/02/10

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

重要事件披露

Form 8-K - Current report
2024/12/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/12/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/15

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/15

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/29

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/29

重要事件披露

Form 8-K - Current report
2024/10/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/10/08

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]